摘要:
Human hPRP4 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of hPRP4 are provided.
摘要:
Human SPHK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SPHK are provided.
摘要:
Human DGK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53,comprising screening for agents that modulate the activity of DKG are provided.
摘要:
Human SPPL genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SPPL are provided.
摘要:
Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.
摘要:
Human CDKL1 genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of CDKL1 are provided.
摘要:
The present invention relates to AUR1 and/or AUR2 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for AUR1 and/or AUR2 related diseases or conditions characterized by an abnormal interaction between a AUR1 and/or AUR2 polypeptide and a AUR1 and/or AUR2 binding partner.
摘要:
The present invention relates to phosphatase polypeptides having the amino acid sequence of SEQ ID NO:23 or SEQ ID NO:24, disclosed herein. The invention also relates to nucleotide sequences encoding the phosphatase polypeptides, vectors and recombinant cells comprising such sequences, antibodies having binding affinity to the phosphatase polypeptides, and other products. Included in the invention are methods for identifying modulators of the phosphatase polypeptides, as well as methods for diagnosing and treating various conditions related to the phosphatase polypeptides.
摘要翻译:本发明涉及具有本文公开的SEQ ID NO:23或SEQ ID NO:24的氨基酸序列的磷酸酶多肽。 本发明还涉及编码磷酸酶多肽的核苷酸序列,载体和包含此类序列的重组细胞,对磷酸酶多肽具有结合亲和力的抗体,以及其它产物。 本发明包括用于鉴定磷酸酶多肽的调节剂的方法,以及用于诊断和治疗与磷酸酶多肽相关的各种病症的方法。
摘要:
The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.
摘要:
The present invention relates to AUR-1 and/or AUR-2 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for AUR-1 and/or AUR-2 related diseases or conditions characterized by an abnormal interaction between a AUR-1 and/or AUR-2 polypeptide and a AUR-1 and/or AUR-2 binding partner.